Also known as: p-Phenylenediamine, CI Developer 13, CI Oxidation Base 10, Developer 13, EINECS 203-404-7 (+15 more)
CAS 106-50-3
1,4-Benzenediamine (CAS 106-50-3) is a chemical substance with GHS signal word Danger; key hazard signal: H331; H311; H301; H319; H317; H400; H410. Key regulatory status: REACH registered, 8 regulatory/inventory lists, cosmetic ingredient cross-reference; source data from ECHA CLP, EPA ToxValDB, EPA CPDat, AICIS, SCCS, IARC, ECHA REACH, ILO ICSC, OSHA, EPA TRI.
1,4-Benzenediamine is classified GHS Danger (H331, H311, H301, H319, H317, H400, H410) in the chemicals database but is restricted in EU cosmetics at max III/8a.
CAS, identifiers, formula, and alternate names for the matched substance record.
Carcinogenic hazard classification from IARC monograph evaluations.
| Group | Meaning | Evaluated | Volume |
|---|---|---|---|
| Group 3 | Not classifiable | 1987 | 16, Sup 7 |
EU harmonized hazard classification, hazard statements, pictograms, and signal word.
| Hazard Class | H-Statements | Pictograms | Signal |
|---|---|---|---|
| Acute Tox. 3 *; Acute Tox. 3 *; Acute Tox. 3 *; Eye Irrit. 2; Skin Sens. 1; Aquatic Acute 1; Aquatic Chronic 1 | H331; H311; H301; H319; H317; H400; H410 | GHS06; GHS09 | Danger |
International Chemical Safety Card hazard and exposure summary.
| Field | Value |
|---|---|
| Short-term Effects | The substance is irritating to the eyes. Inhalation of dust may cause asthmatic reactions. See Notes. Ingestion could cause swelling of mouth and throat. The substance may cause effects on the blood. This may result in the formation of methaemoglobin. Exposure could cause death. |
| Long-term Effects | Repeated or prolonged contact may cause skin sensitization. Repeated or prolonged inhalation may cause asthma. The substance may have effects on the kidneys. This may result in kidney impairment. |
| Routes of Exposure | The substance can be absorbed into the body by inhalation, through the skin and by ingestion. |
Occupational exposure limits from OSHA, NIOSH, and ACGIH rows.
| Agency | Metric | Value | ppm | mg/m3 | Skin |
|---|---|---|---|---|---|
| OSHA | TWA | 0.1 mg/m³ | - | 0.1 | Y |
| NIOSH | TWA | 0.1 mg/m³ | - | 0.1 | Y |
| ACGIH | TWA | 0.1 mg/m³ [1988] | - | 0.1 | Y |
| CAL/OSHA | TWA | 0.1 mg/m³ | - | 0.1 | Y |
| NIOSH | IDLH | 25 mg/m³ | - | 25 | - |
Industrial and product-use categories associated with this substance.
Inventory, screening, and regulatory list matches from public chemical databases.
| List | Keyword | Source |
|---|---|---|
| Indirect additives food contact (10/2018) | FDA | United States Food and Drug Administration (FDA) |
| Europe; Personal care - hair coloring | Danish Environmental Protection Agency | Danish EPA |
| detected; Europe; Personal care - hair coloring | Danish Environmental Protection Agency | Danish EPA |
| detected; Europe; Personal care - hair coloring | Danish Environmental Protection Agency | Danish EPA |
| - | Regulatory Toxicology and Pharmacology | Published Articles |
| Canada; pharmaceutical | DrugBank | DrugBank |
| Canada; pharmaceutical | DrugBank | DrugBank |
| Europe; Personal care - hair coloring | Danish Environmental Protection Agency | Danish EPA |
Toxicology endpoints rendered from public NOAEL study rows.
| Value | Unit | Endpoint | Route | Species | Source |
|---|---|---|---|---|---|
| 1 | % | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 1 | % | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 1 | % | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 1 | % | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 1 | % | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 1 | % | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 2 | % | - | - | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | mg/kg/day | - | oral | rat | UnifiedCodex:SCCNFP:beta.noael_studies |
| 4 | mg/kg bw | - | - | - | UnifiedCodex:SCCNFP:beta.noael_studies |
| 4 | mg/kg | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | mg/kg bw/day | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | mg/kg bw/d | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | mg/kg bw/d | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | mg/kg bw/d | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | mg/kg bw/d | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | mg/kg bw/d | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | mg/kg bw/d | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | mg/kg bw/d | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | mg/kg bw | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | mg/kg bw/d | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | mg/kg bw/d | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | mg/kg bw/d | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | - | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 4 | - | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| <5 | mg/kg bw/day | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 6.45 | mg/kg bw | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 6.45 | mg/kg bw | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 8 | mg/kg | - | dermal | rabbit | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 8 | mg/kg bw | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 8 | mg/kg bw/d | - | dermal | rabbit | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 8 | mg/kg bw/day | - | - | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 8 | - | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 8 | - | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 14 | - | - | - | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 16 | mg/kg bw | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 16 | mg/kg bw | - | dermal | rabbit | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 16 | mg/kg bw | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 16 | mg/kg bw/d | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 16 | mg/kg bw/d | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 16 | mg/kg bw/d | - | dermal | rabbit | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 16 | mg/kg bw/d | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 16 | mg/kg bw/d | - | - | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 16 | - | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 16 | - | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 50 | mg/kg bw | - | oral | rat | UnifiedCodex:SCCNFP:beta.noael_studies |
| 50 | mg/kg bw | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 50 | mg/kg bw | - | oral | rat | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 50 | - | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 50 | - | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
| 61 | - | - | oral | - | UnifiedCodex:SCCS_SHADOW:beta.noael_studies |
Showing 50 of 100 studies
Registration status from the ECHA REACH registered substances database.
| Status | Name | EC Number | Link |
|---|---|---|---|
| Registered | p-phenylenediamine | 203-404-7 | ECHA overview → |
TRI hazard and reporting flags for the matched chemical.
| Chemical | Category | Flags |
|---|---|---|
| p-Phenylenediamine | - | - |
Australian industrial chemicals inventory status and applicable conditions.
EU Scientific Committee opinions tied to the matched substance.
| Opinion | Date | Conclusion | Max Conc. | Concerns |
|---|---|---|---|---|
| SCCS/1443/12 | 26-27 June 2012 | safe with restrictions | 2.0% | strong sensitiser; MoS >100 for systemic; labelling required |
| SCCP/0976/06 | 10 October 2006 | safe with restrictions | 2.0% | strong sensitiser; labelling required |
Same-CAS cosmetic ingredient record for cross-vertical context.
Same-CAS pharmaceutical records from drug and bioactivity sources.
1,4-Benzenediamine (CAS 106-50-3) is classified under EU CLP Annex VI as Acute Tox. 3 *; Acute Tox. 3 *; Acute Tox. 3 *; Eye Irrit. 2; Skin Sens. 1; Aquatic Acute 1; Aquatic Chronic 1 with signal word Danger. Hazard statements: H331; H311; H301; H319; H317; H400; H410. Source: EU CLP Annex VI (ECHA).
1,4-Benzenediamine has 100 NOAEL studies in the database. The lowest reported value is 0.001429 % via Dermal in Human. Source: NTP_ICE_skin_sensitization.
1,4-Benzenediamine appears on 4 regulatory/inventory lists including Indirect additives food contact (10/2018), Europe; Personal care - hair coloring, detected; Europe; Personal care - hair coloring, and 1 more. Source: EPA CPDat.
1,4-Benzenediamine is classified by IARC as Group 3 — not classifiable as to its carcinogenicity to humans (evaluated 1987). Source: IARC Monographs on the Identification of Carcinogenic Hazards to Humans.
Occupational exposure limits for 1,4-Benzenediamine are set by OSHA, NIOSH, ACGIH. 5 limit values from official agencies are documented in the database. Source: OSHA, NIOSH, ACGIH.
Yes, 1,4-Benzenediamine is also indexed as a cosmetic ingredient under the name P-PHENYLENEDIAMINE. View the full cosmetic safety profile on the ingredient page for detailed safety data, SCCS opinions, and regulatory status.
Safety data is sourced from ECHA CLP Annex VI, EPA ToxValDB, EPA CPDat, AICIS (Australian Industrial Chemicals Introduction Scheme), EPA DSSTox, IARC Monographs, ECHA REACH, ILO/WHO ICSC, OSHA/NIOSH/ACGIH, EPA Toxics Release Inventory, CosIng / Ingredients DB, ChEMBL / DailyMed. All data traces to primary regulatory sources and is updated from official government databases.
1,4-Benzenediamine is classified GHS Danger (H331, H311, H301, H319, H317, H400, H410) in the chemicals database but is restricted in EU cosmetics at max III/8a.
1,4-Benzenediamine also appears in cosmetics, pharmaceutical databases.